Skip to content
2000
Volume 21, Issue 6
  • ISSN: 1573-403X
  • E-ISSN: 1875-6557

Abstract

Heart failure remains a significant global health challenge, necessitating continuous advancements in management strategies to improve patient outcomes. This review aimed to elucidate the current scenario of heart failure and its management in the modern era, focusing on integrating medical therapy and implantable device interventions. According to guidelines, medical treatment remains the primary method of treating heart failure. Such medications include ACE inhibitors, neprilysin-angiotensin receptor inhibitors, beta-blockers, angiotensin II receptor blockers, mineralocorticoid receptor antagonists, and blockers of sodium-glucose co-transporter-2. These pharmacologic agents have demonstrated efficacy in decreasing mortality and morbidity in patients. The advent of implantable devices has revolutionized treatment, providing substantial benefits in specific patient populations. Cardiac resynchronization therapy has emerged as a pivotal intervention for patients with reduced ejection fraction and dyssynchronous ventricular contraction, effectively enhancing cardiac function and quality of life. Furthermore, left bundle branch area pacing improvements provide fascinating alternatives to traditional cardiac resynchronization therapy. The essential significance of device-based therapies is further highlighted by the function of implanted cardioverter-defibrillators in preventing unexpected cardiac deaths in high-risk patients. Furthermore, integrating remote monitoring technologies and novel device innovations continues to enhance the precision and efficacy of heart failure management. This review comprehensively examines current guidelines and evidence supporting the use of these therapies, addressing their synergistic potential and the practical considerations for their implementation, while synthesizing recent advancements in pharmacologic and device-based interventions.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ccr/10.2174/011573403X338702250226075044
2025-03-13
2025-10-12

  • From This Site

    /content/journals/ccr/10.2174/011573403X338702250226075044
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. AndreevaE.R. PugachI.M. OrekhovA.N. Subendothelial smooth muscle cells of human aorta express macrophage antigen in situ and in vitro.Atherosclerosis19971351192710.1016/S0021‑9150(97)00136‑6 9395269
     [Google Scholar]
  2. AujeskyD. ObroskyD.S. StoneR.A. Derivation and validation of a prognostic model for pulmonary embolism.Am. J. Respir. Crit. Care Med.200517281041104610.1164/rccm.200506‑862OC 16020800
     [Google Scholar]
  3. AuneD SenA ó’HartaighB Resting heart rate and the risk of cardiovascular disease, total cancer, and all-cause mortality – A systematic review and dose–response meta-analysis of prospective studies.Nutr. Metab. Cardiovasc. Dis.201727650451710.1016/j.numecd.2017.04.004 28552551
     [Google Scholar]
  4. BainbridgeM.N. LiL. TanY. CheongB.Y. MarianA.J. Identification of established arrhythmogenic right ventricular cardiomyopathy mutation in a patient with the contrasting phenotype of hypertrophic cardiomyopathy.BMC Med. Genet.20171812410.1186/s12881‑017‑0385‑8 28253841
     [Google Scholar]
  5. BasiliS. RaparelliV. VestriA. TannaG.L.D. VioliF. Comparison of efficacy of antiplatelet treatments for patients with claudication.Thromb. Haemost.2010103476677310.1160/TH09‑09‑0635 20174763
     [Google Scholar]
  6. BasmanC. RashidU. ParmarY.J. KligerC. KronzonI. The role of percutaneous vacuum-assisted thrombectomy for intracardiac and intravascular pathology.J. Card. Surg.2018331066667210.1111/jocs.13806 30187515
     [Google Scholar]
  7. BauriedelG. HutterR. WelschU. BachR. SievertH. LüderitzB. Role of smooth muscle cell death in advanced coronary primary lesions: implications for plaque instability.Cardiovasc. Res.199941248048810.1016/S0008‑6363(98)00318‑6 10341848
     [Google Scholar]
  8. BeebeH.G. DawsonD.L. CutlerB.S. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial.Arch. Intern. Med.1999159172041205010.1001/archinte.159.17.2041 10510990
     [Google Scholar]
  9. BergerJ.S. AbramsonB.L. LopesR.D. Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.Vasc. Med.201823652353010.1177/1358863X18775594 29992857
     [Google Scholar]
  10. BelchJ.J.F. DormandyJ. BiasiG.M. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.J. Vasc. Surg.201052482583310.1016/j.jvs.2010.04.027 20678878
     [Google Scholar]
  11. BennettM.R. SinhaS. OwensG.K. Vascular smooth muscle cells in atherosclerosis.Circ. Res.2016118469270210.1161/CIRCRESAHA.115.306361 26892967
     [Google Scholar]
  12. BergerJ. HeizerG. BaumgartnerI. Ticagrelor in patientswtih symptomatic peripheral artery disease and prior coronary artery disease.Eur. Heart J.201723652353010.1177/1358863X18775594 29992857
     [Google Scholar]
  13. BergqvisD. Platelet inhibition with ASA/dipyridamole after percutaneous balloon angioplasty in patients with symptomatic lower limb arterial disease. A prospective double-blind trial.Eur. J. Vasc. Surg.199481838810.1016/S0950‑821X(05)80126‑4 8307222
     [Google Scholar]
  14. BhattA.S. DeVoreA.D. DeWaldT.A. SwedbergK. MentzR.J. Achieving a maximally tolerated β-blocker dose in heart failure patients.J. Am. Coll. Cardiol.201769202542255010.1016/j.jacc.2017.03.563 28521892
     [Google Scholar]
  15. BhattD.L. FlatherM.D. HackeW. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.J. Am. Coll. Cardiol.200749191982198810.1016/j.jacc.2007.03.025 17498584
     [Google Scholar]
  16. BhonsaleA. JamesC.A. TichnellC. Risk stratification in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers.Circ. Arrhythm. Electrophysiol.20136356957810.1161/CIRCEP.113.000233 23671136
     [Google Scholar]
  17. BlanchardJ. CarrerasL.O. KindermansM. Results of EMATAP:] A double-blind placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease.Nouv. Rev. Fr. Hematol.1994356523528 8152898
     [Google Scholar]
  18. BocchiE.A. BöhmM. BorerJ.S. Effect of combining ivabradine and β-blockers: Focus on the use of carvedilol in the shift population.Cardiology2015131421822410.1159/000380812 25968495
     [Google Scholar]
  19. BonacaM.P. NaultP. GiuglianoR.P. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease.Circulation2018137433835010.1161/CIRCULATIONAHA.117.032235 29133605
     [Google Scholar]
  20. BorerJ.S. BöhmM. FordI. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: The SHIFT study.Eur. Heart J.201233222813282010.1093/eurheartj/ehs259 22927555
     [Google Scholar]
  21. BüllerH.R. PrinsM.H. LensinA.W. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.N. Engl. J. Med.2012366141287129710.1056/NEJMoa1113572 22449293
     [Google Scholar]
  22. CaldwellJ. RedfearnD. ChialeP.A. BaranchukA. Ablation-induced epsilon wave.Heart Rhythm201310111737173810.1016/j.hrthm.2012.08.038 23102627
     [Google Scholar]
  23. ChangJ.R. DuanX.H. ZhangB.H. Intermedin1-53 attenuates vascular smooth muscle cell calcification by inhibiting endoplasmic reticulum stress via cyclic adenosine monophosphate/protein kinase A pathway.Exp. Biol. Med. (Maywood)2013238101136114610.1177/1535370213502619 24006303
     [Google Scholar]
  24. ChatterjeeS. ChakrabortyA. WeinbergI. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: A meta-analysis.JAMA2014311232414242110.1001/jama.2014.5990 24938564
     [Google Scholar]
  25. ChauhanM.S. KawamuraA. Percutaneous rheolytic thrombectomy for large pulmonary embolism: A promising treatment option.Catheter. Cardiovasc. Interv.200770112313010.1002/ccd.20997 17421019
     [Google Scholar]
  26. ClarkeM.C.H. FiggN. MaguireJ.J. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis.Nat. Med.20061291075108010.1038/nm1459 16892061
     [Google Scholar]
  27. CroonsV. MartinetW. HermanA.G. De MeyerG.R.Y. Differential effect of the protein synthesis inhibitors puromycin and cycloheximide on vascular smooth muscle cell viability.J. Pharmacol. Exp. Ther.2008325382483210.1124/jpet.107.132944 18322149
     [Google Scholar]
  28. DalyC.A. ClemensF. Lopez SendonJ.L. Inadequate control of heart rate in patients with stable angina: Results from the European Heart Survey.Postgrad. Med. J.201086101421221710.1136/pgmj.2009.084384 20354044
     [Google Scholar]
  29. DonaldsonC.W. BakerJ.N. NarayanR.L. Thrombectomy using suction filtration and veno‐venous bypass: Single center experience with a novel device.Catheter. Cardiovasc. Interv.2015862E81E8710.1002/ccd.25583 24975395
     [Google Scholar]
  30. GalG. FineM.J. RoyP-M. Prospective validation of the Pulmonary Embolism Severity Index. A clinical prognostic model for pulmonary embolism.Thromb. Haemost.2008100594394810.1160/TH08‑05‑0285 18989542
     [Google Scholar]
  31. DumantepeM. TeymenB. AkturkU. SerenM. Efficacy of rotational thrombectomy on the mortality of patients with massive and submassive pulmonary embolism.J. Card. Surg.201530432433210.1111/jocs.12521 25683156
     [Google Scholar]
  32. DzauV.J. Braun-DullaeusR.C. SeddingD.G. Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies.Nat. Med.20028111249125610.1038/nm1102‑1249 12411952
     [Google Scholar]
  33. FasulloS. ScalzoS. MaringhiniG. Six-month echocardiographic study in patients with submassive pulmonary embolism and right ventricle dysfunction: comparison of thrombolysis with heparin.Am. J. Med. Sci.20113411333910.1097/MAJ.0b013e3181f1fc3e 20890176
     [Google Scholar]
  34. FerrariR. FoxK. Heart rate reduction in coronary artery disease and heart failure.Nat. Rev. Cardiol.201613849350110.1038/nrcardio.2016.84 27226153
     [Google Scholar]
  35. FontaineG. FontaliranF. HébertJ.L. Arrhythmogenic right ventricular dysplasia.Annu. Rev. Med.1999501173510.1146/annurev.med.50.1.17 10073261
     [Google Scholar]
  36. FontaineG. FontaliranF. Arrhythmogenic right ventricular dysplasia masquerading as dilated cardiomyopathy.Am. J. Cardiol.19998491143 10569693
     [Google Scholar]
  37. FontaineG. GuiraudonG. FrankR. Simulation studies and epicardial mapping in ventricular tachycardia: Study of mechanisms and selection for surgery. Re-entrant Arrhythmias Mechanisms and Treatment.Lancaster, UKMTP Pub.1977334350
     [Google Scholar]
  38. FoxK. FordI. StegP.G. TardifJ.C. TenderaM. FerrariR. Ivabradine in stable coronary artery disease without clinical heart failure.N. Engl. J. Med.2014371121091109910.1056/NEJMoa1406430 25176136
     [Google Scholar]
  39. FoxK. FordI. StegP.G. TenderaM. RobertsonM. FerrariR. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A subgroup analysis of a randomised controlled trial.Lancet2008372964181782110.1016/S0140‑6736(08)61171‑X 18757091
     [Google Scholar]
  40. GeorgeB.A. KoJ.M. LensingF.D. KuiperJ.J. RobertsW.C. “Repaired” tetralogy of fallot mimicking arrhythmogenic right ventricular cardiomyopathy (another phenocopy).Am. J. Cardiol.2011108232632910.1016/j.amjcard.2011.03.042 21545987
     [Google Scholar]
  41. GiavariniA. de SilvaR. The role of ivabradine in the management of angina pectoris.Cardiovasc. Drugs Ther.201630440741710.1007/s10557‑016‑6678‑x 27475447
     [Google Scholar]
  42. GottschalkB. GyselM. Barbosa-BarrosR. The use of fontaine leads in the diagnosis of arrhythmogenic right ventricular dysplasia.Ann. Noninvasive Electrocardiol.201419327928410.1111/anec.12153 24597934
     [Google Scholar]
  43. HabalM.V. LiuP.P. AustinP.C. Association of heart rate at hospital discharge with mortality and hospitalizations in patients with heart failure.Circ. Heart Fail.201471122010.1161/CIRCHEARTFAILURE.113.000429 24297690
     [Google Scholar]
  44. HamillV. FordI. FoxK. Repeated heart rate measurement and cardiovascular outcomes in left ventricular systolic dysfunction.Am. J. Med.20151281011021108.e610.1016/j.amjmed.2015.04.042 26044936
     [Google Scholar]
  45. HeidenreichP.A. BozkurtB. AguilarD. 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines.Circulation202214518e895e103210.1161/CIR.0000000000001063 35363499
     [Google Scholar]
  46. HendersonE.L. GengY.J. SukhovaG.K. WhittemoreA.D. KnoxJ. LibbyP. Death of smooth muscle cells and expression of mediators of apoptosis by T lymphocytes in human abdominal aortic aneurysms.Circulation19999919610410.1161/01.CIR.99.1.96 9884385
     [Google Scholar]
  47. HiattW. A study comparing cardiovascular effects of ticagrelor and clopidogrel in patients with peripheral artery disease (EUCLID).2017Available at https://clinicaltrials.gov/ct2/show/results/NCT01732822
    [Google Scholar]
  48. HiattW.R. MoneyS.R. BrassE.P. Long-term safety of cilostazol in patients with peripheral artery disease: The CASTLE study (Cilostazol: A Study in Long-term Effects).J. Vasc. Surg.2008472330336.e210.1016/j.jvs.2007.10.009 18155871
     [Google Scholar]
  49. HoogendijkM.G. Diagnostic dilemmas: Overlapping features of brugada syndrome and arrhythmogenic right ventricular cardiomyopathy.Front. Physiol.2012314410.3389/fphys.2012.00144 22654761
     [Google Scholar]
  50. HurstJ.W. Naming of the waves in the ECG, with a brief account of their genesis.Circulation199898181937194210.1161/01.CIR.98.18.1937 9799216
     [Google Scholar]
  51. FudimM. AbrahamW.T. von BardelebenR.S. Device therapy in chronic heart failure.J. Am. Coll. Cardiol.202178993195610.1016/j.jacc.2021.06.040 34446165
     [Google Scholar]
  52. IbrahimN.E. GagginH.K. TurchinA. Heart rate, beta-blocker use, and outcomes of heart failure with reduced ejection fraction.Eur. Heart J. Cardiovasc. Pharmacother.20195131110.1093/ehjcvp/pvy011 29490032
     [Google Scholar]
  53. IidaO. YokoiH. SogaY. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the sufficient treatment of peripheral intervention by cilostazol study.Circulation2013127232307231510.1161/CIRCULATIONAHA.112.000711 23652861
     [Google Scholar]
  54. IyemereV.P. ProudfootD. WeissbergP.L. ShanahanC.M. Vascular smooth muscle cell phenotypic plasticity and the regulation of vascular calcification.J. Intern. Med.2006260319221010.1111/j.1365‑2796.2006.01692.x 16918817
     [Google Scholar]
  55. JanzonL. BergqvistD. BobergJ. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study.J. Intern. Med.1990227530130810.1111/j.1365‑2796.1990.tb00164.x 2187948
     [Google Scholar]
  56. JaoudeS.A. LeclercqJ.F. CoumelP. Progressive ECG changes in arrhythmogenic right ventricular disease Evidence foran evolving disease.Eur. Heart J.199617111717172210.1093/oxfordjournals.eurheartj.a014756 8922921
     [Google Scholar]
  57. JiménezD. AujeskyD. MooresL. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism.Arch. Intern. Med.2010170151383138910.1001/archinternmed.2010.199 20696966
     [Google Scholar]
  58. JonesW.S. BaumgartnerI. HiattW.R. International steeringcommittee and investigators of the euclid trial. ticagrelorcompared with clopidogrel in patients with prior lower extremity revascularization for peripheral artery disease.Circulation2017135324125010.1161/CIRCULATIONAHA.116.025880 27840336
     [Google Scholar]
  59. JukemaJ.W. SzarekM. ZijlstraL.E. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome.J. Am. Coll. Cardiol.20197491167117610.1016/j.jacc.2019.03.013 30898609
     [Google Scholar]
  60. KapustinA.N. ShanahanC.M. Calcium regulation of vascular smooth muscle cell-derived matrix vesicles.Trends Cardiovasc. Med.201222513313710.1016/j.tcm.2012.07.009 22902179
     [Google Scholar]
  61. KarsentyG. KronenbergH.M. SettembreC. Genetic control of bone formation.Annu. Rev. Cell Dev. Biol.200925162964810.1146/annurev.cellbio.042308.113308 19575648
     [Google Scholar]
  62. KaskiJ.C. GloeklerS. FerrariR. Role of ivabradine in management of stable angina in patients with different clinical profiles.Open Heart201851e00072510.1136/openhrt‑2017‑000725 29632676
     [Google Scholar]
  63. KatsanosK. SpiliopoulosS. SahaP. Comparative efficacy and safety of different antiplatelet agents for prevention of major cardiovascular events and leg amputations in patients with peripheral arterial disease: A systematic review and network meta-analysis.PLoS One2015108e013569210.1371/journal.pone.0135692 26274912
     [Google Scholar]
  64. KauL.U. NatrajanS. DalalJ. SaranR.K. Prevalence and control of cardiovascular risk factors in stable coronary artery outpatients in India compared with the rest of the world: An analysis from international CLARIFY registry.Indian Heart J.201769444745210.1016/j.ihj.2017.05.014 28822509
     [Google Scholar]
  65. KaulU. WanderG.S. SinhaN. Self-blood pressure measurement as compared to office blood pressure measurement in a large Indian population; the India Heart Study.J. Hypertens.20203871262127010.1097/HJH.0000000000002410 32195821
     [Google Scholar]
  66. KediX. MingY. YongpingW. YiY. XiaoxiangZ. Free cholesterol overloading induced smooth muscle cells death and activated both ER- and mitochondrial-dependent death pathway.Atherosclerosis2009207112313010.1016/j.atherosclerosis.2009.04.019 19467656
     [Google Scholar]
  67. KenigsbergD.N. KalahastyG. GrizzardJ.D. WoodM.A. EllenbogenK.A. Images in cardiovascular medicine. Intracardiac correlate of the epsilon wave in a patient with arrhythmogenic right ventricular dysplasia.Circulation200711521e538e53910.1161/CIRCULATIONAHA.106.685594 17533186
     [Google Scholar]
  68. KhanM.I. PichnaB.A. ShiY. BowesA.J. WerstuckG.H. Evidence supporting a role for endoplasmic reticulum stress in the development of atherosclerosis in a hyperglycaemic mouse model.Antioxid. Redox Signal.20091192289229810.1089/ars.2009.2569 19548776
     [Google Scholar]
  69. KièsP. BootsmaM. BaxJ.J. Serial reevaluation for ARVD/C is indicated in patients presenting with left bundle branch block ventricular tachycardia and minor ECG abnormalities.J. Cardiovasc. Electrophysiol.200617658659310.1111/j.1540‑8167.2006.00442.x 16836703
     [Google Scholar]
  70. KomajdaM. TavazziL. SwedbergK. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: A post‐hoc analysis of SHIFT.Eur. J. Heart Fail.20161891182118910.1002/ejhf.582 27210035
     [Google Scholar]
  71. KonstantinidesS. GeibelA. OlschewskiM. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: Results of a multicenter registry.Circulation199796388288810.1161/01.CIR.96.3.882 9264496
     [Google Scholar]
  72. KonstantinidesS. TiedeN. GeibelA. OlschewskiM. JustH. KasperW. Comparison of alteplase versus heparin for resolution of major pulmonary embolism.Am. J. Cardiol.199882896697010.1016/S0002‑9149(98)00513‑X 9794353
     [Google Scholar]
  73. KonstantinidesS.V. MeyerG. BecattiniC. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS).Eur. Respir. J.2019543190164710.1183/13993003.01647‑2019 31473594
     [Google Scholar]
  74. KoruthJ.S. LalaA. PinneyS. ReddyV.Y. DukkipatiS.R. The clinical use of ivabradine.J. Am. Coll. Cardiol.201770141777178410.1016/j.jacc.2017.08.038 28958335
     [Google Scholar]
  75. KurganskyK.E. SchubertP. ParkerR. Association of pulse rate with outcomes in heart failure with reduced ejection fraction: A retrospective cohort study.BMC Cardiovasc. Disord.20202019210.1186/s12872‑020‑01384‑6 32101141
     [Google Scholar]
  76. LamC.S.P. TengT.H.K. TayW.T. Regional and ethnic differences among patients with heart failure in Asia: The Asian sudden cardiac death in heart failure registry.Eur. Heart J.201637413141315310.1093/eurheartj/ehw331 27502121
     [Google Scholar]
  77. Larroque-CardosoP. SwiaderA. IngueneauC. Role of protein kinase C δ in ER stress and apoptosis induced by oxidized LDL in human vascular smooth muscle cells.Cell Death Dis.201342e52010.1038/cddis.2013.47 23449456
     [Google Scholar]
  78. LetsasK.P. EfremidisM. WeberR. Epsilon-like waves and ventricular conduction abnormalities in subjects with type 1 ECG pattern of Brugada syndrome.Heart Rhythm20118687487810.1016/j.hrthm.2011.01.043 21315837
     [Google Scholar]
  79. LiG.L. SagunerA.M. FontaineG.H. FrankR. Epsilon waves: Milestones in the discovery and progress.Ann. Noninvasive Electrocardiol.2018236e1257110.1111/anec.12571 29978588
     [Google Scholar]
  80. LibbyP. RidkerP.M. HanssonG.K. Progress and challenges in translating the biology of atherosclerosis.Nature2011473734731732510.1038/nature10146 21593864
     [Google Scholar]
  81. LibermanM. JohnsonR.C. HandyD.E. LoscalzoJ. LeopoldJ.A. Bone morphogenetic protein-2 activates NADPH oxidase to increase endoplasmic reticulum stress and human coronary artery smooth muscle cell calcification.Biochem. Biophys. Res. Commun.2011413343644110.1016/j.bbrc.2011.08.114 21907184
     [Google Scholar]
  82. LinkM.S. LaidlawD. PolonskyB. Ventricular arrhythmias in the North American multidisciplinary study of ARVC: Predictors, characteristics, and treatment.J. Am. Coll. Cardiol.201464211912510.1016/j.jacc.2014.04.035 25011714
     [Google Scholar]
  83. LiuH. LiX. QinF. HuangK. Selenium suppresses oxidative-stress-enhanced vascular smooth muscle cell calcification by inhibiting the activation of the PI3K/AKT and ERK signaling pathways and endoplasmic reticulum stress.J. Biol. Inorg. Chem.201419337538810.1007/s00775‑013‑1078‑1 24390545
     [Google Scholar]
  84. LiuX. JohnsonM. MardekianJ. PhatakH. ThompsonJ. CohenA.T. Apixaban reduces hospitalizations in patients with venous thromboembolism: An analysis of the apixaban for the initial management of pulmonary embolism and deep-vein thrombosis as first-line therapy (AMPLIFY) trial.J. Am. Heart Assoc.2015412e00234010.1161/JAHA.115.002340 26627879
     [Google Scholar]
  85. LiuY. DrozdovI. ShroffR. BeltranL.E. ShanahanC.M. Prelamin A accelerates vascular calcification via activation of the DNA damage response and senescence-associated secretory phenotype in vascular smooth muscle cells.Circ. Res.201311210e99e10910.1161/CIRCRESAHA.111.300543 23564641
     [Google Scholar]
  86. LondonG.M. Arterial calcification: Cardiovascular function and clinical outcome.Nefrología2011316644647 22130278
     [Google Scholar]
  87. LuY. BianY. WangY. BaiR. WangJ. XiaoC. Globular adiponectin reduces vascular calcification via inhibition of ER-stress-mediated smooth muscle cell apoptosis.Int. J. Clin. Exp. Pathol.20158325452554 26045760
     [Google Scholar]
  88. MaddoxT.M. JanuzziJ.L.Jr AllenL.A. 2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: Answers to 10 pivotal issues about heart failure with reduced ejection fraction.J. Am. Coll. Cardiol.202177677281010.1016/j.jacc.2020.11.022 33446410
     [Google Scholar]
  89. MalabananK.P. KanellakisP. BobikA. KhachigianL.M. Activation transcription factor-4 induced by fibroblast growth factor-2 regulates vascular endothelial growth factor-A transcription in vascular smooth muscle cells and mediates intimal thickening in rat arteries following balloon injury.Circ. Res.2008103437838710.1161/CIRCRESAHA.107.168682 18617696
     [Google Scholar]
  90. MasudaM. Miyazaki-AnzaiS. KeenanA.L. Saturated phosphatidic acids mediate saturated fatty acid–induced vascular calcification and lipotoxicity.J. Clin. Invest.2015125124544455810.1172/JCI82871 26517697
     [Google Scholar]
  91. MasudaM. TingT.C. LeviM. SaundersS.J. Miyazaki-AnzaiS. MiyazakiM. Activating transcription factor 4 regulates stearate-induced vascular calcification.J. Lipid Res.20125381543155210.1194/jlr.M025981 22628618
     [Google Scholar]
  92. McDonaghT.A. MetraM. AdamoM. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.Eur. Heart J.202142363599372610.1093/eurheartj/ehab368 34447992
     [Google Scholar]
  93. MullasariA. MahajanA. ChananaB.B. Efficacy and safety of ivabradine once-daily prolonged-release versus twice-daily immediate- release formulation in patients with stable chronic heart failure with systolic dysfunction: A randomized, double-blind, phase 3 non-inferiority (PROFICIENT) study.Cardiol. Ther.20209250552110.1007/s40119‑020‑00200‑8 33006062
     [Google Scholar]
  94. NevenE. DauweS. De BroeM.E. D’HaeseP.C. PersyV. Endochondral bone formation is involved in media calcification in rats and in men.Kidney Int.200772557458110.1038/sj.ki.5002353 17538568
     [Google Scholar]
  95. PadmanabhanT.N.C. DaniS. ChopraV.K. GuhaS. VasnawalaH. AmmarR. Prevalence of sympathetic overactivity in hypertensive patients – A pan India, non-interventional, cross sectional study.Indian Heart J.201466668669010.1016/j.ihj.2014.10.421 25634406
     [Google Scholar]
  96. PetersS. TrümmelM. Diagnosis of arrhythmogenic right ventricular dysplasia-cardiomyopathy: Value of standard ECG revisited.Ann. Noninvasive Electrocardiol.20038323824510.1046/j.1542‑474X.2003.08312.x 14510660
     [Google Scholar]
  97. PlatonovP.G. CalkinsH. HauerR.N. High interobserver variability in the assessment of epsilon waves: Implications for diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia.Heart Rhythm201613120821610.1016/j.hrthm.2015.08.031 26304715
     [Google Scholar]
  98. PlatonovP.G. HaugaaK.H. BundgaardH. Primary prevention of sudden cardiac death with implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular cardiomyopathy.Am. J. Cardiol.201912371156116210.1016/j.amjcard.2018.12.049 30678832
     [Google Scholar]
  99. ProudfootD. ShanahanC.M. Biology of calcification in vascular cells: Intima versus media.Herz200126424525110.1007/PL00002027 11479936
     [Google Scholar]
  100. ProudfootD. SkepperJ.N. HegyiL. BennettM.R. ShanahanC.M. WeissbergP.L. Apoptosis regulates human vascular calcification] in vitro: Evidence for initiation of vascular calcification by apoptotic bodies.Circ. Res.200087111055106210.1161/01.RES.87.11.1055 11090552
     [Google Scholar]
  101. QiaoJ.H. MertensR.B. FishbeinM.C. GellerS.A. Cartilaginous metaplasia in calcified diabetic peripheral vascular disease: Morphologic evidence of enchondral ossification.Hum. Pathol.200334440240710.1053/hupa.2003.72 12733123
     [Google Scholar]
  102. SantucciP MortonJ PickenM WilberD Electroanatomic mapping of the right ventricle in a patient with a giant epsilon wave, ventricular tachycardia, and cardiac sarcoidosis20041591091410.1046/j.1540‑8167.2004.03708.x 15363085
     [Google Scholar]
  103. RaoD. BalagopalanJ.P. SharmaA. ChauhanV.C. JhalaD. BEAT survey: A cross-sectional study of resting heart rate in young (18-55 year) hypertensive patients.J. Assoc. Physicians India20156351417 26591139
     [Google Scholar]
  104. RaoM.S. MandalS. Epidemiologic surveillance on quality of life in patients with systolic heart failure after treatment with the selective heart rate inhibitor ivabradine.J. Pract. Cardiovasc. Sci.20173210010210.4103/jpcs.jpcs_8_17
     [Google Scholar]
  105. RennenbergR. KesselsA.G.H. SchurgersL.J. Van EngelshovenJ.M.A. de LeeuwP. KroonA.A. Vascular calcifications as a marker of increased cardiovascular risk: A meta-analysis.Vasc. Health Risk Manag.20095118519710.2147/VHRM.S4822 19436645
     [Google Scholar]
  106. RongJ.X. ShapiroM. TroganE. FisherE.A. Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading.Proc. Natl. Acad. Sci. USA200310023135311353610.1073/pnas.1735526100 14581613
     [Google Scholar]
  107. SageA.P. TintutY. DemerL.L. Regulatory mechanisms in vascular calcification.Nat. Rev. Cardiol.20107952853610.1038/nrcardio.2010.115 20664518
     [Google Scholar]
  108. SenguptaS.P. BurkuleN. BansalM. Normative values of cardiac chamber dimensions and global longitudinal strain in Indians: The Indian Normative Data of Echocardiography Analyzed (INDEA) study.Int. J. Cardiovasc. Imaging202137387188010.1007/s10554‑020‑02060‑8 33047178
     [Google Scholar]
  109. SerranoR.L. YuW. TerkeltaubR. Mono-allelic and bi-allelic ENPP1 deficiency promote post-injury neointimal hyperplasia associated with increased C/EBP homologous protein expression.Atherosclerosis2014233249350210.1016/j.atherosclerosis.2014.01.003 24530784
     [Google Scholar]
  110. ShanahanC.M. CaryN.R.B. SalisburyJ.R. ProudfootD. WeissbergP.L. EdmondsM.E. Medial localization of mineralization-regulating proteins in association with Mönckeberg’s sclerosis: Evidence for smooth muscle cell-mediated vascular calcification.Circulation1999100212168217610.1161/01.CIR.100.21.2168 10571976
     [Google Scholar]
  111. ShanahanC.M. WeissbergP.L. MetcalfeJ.C. Isolation of gene markers of differentiated and proliferating vascular smooth muscle cells.Circ. Res.199373119320410.1161/01.RES.73.1.193 8508530
     [Google Scholar]
  112. ShanahanC.M. Vascular calcification.Curr. Opin. Nephrol. Hypertens.200514436136710.1097/01.mnh.0000172723.52499.38 15931005
     [Google Scholar]
  113. ShankmanL.S. GomezD. CherepanovaO.A. KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis.Nat. Med.201521662863710.1038/nm.3866 25985364
     [Google Scholar]
  114. ShrivastavaA. GoyalM.K. GuptaJ.K. Epileptogenic drugs and seizures: A comprehensive review of current knowledge.Int J Pharm Res2020122411
     [Google Scholar]
  115. ShrivastavaA. GuptaJ.K. GoyalM.K. Flavonoids and antiepileptic drugs: A comprehensive review on their neuroprotective potentials.J Med P’ceutical Allied Sci20221114179418610.55522/jmpas.V11I1.2175
     [Google Scholar]
  116. ShrivastavaA. GuptaJ.K. GoyalM.K. Neuroprotective efficacy of quercetin with lamotrigine and gabapentin against pentylenetetrazole- Induced kindling and associated behavioral comorbidities in mice.Indian J Pharmaceut Educ Res2022564ss659s66810.5530/ijper.56.4s.212
     [Google Scholar]
  117. StegP.G. FerrariR. FordI. Heart rate and use of beta-blockers in stable outpatients with coronary artery disease.PLoS One201275e3628410.1371/journal.pone.0036284 22570699
     [Google Scholar]
  118. UhlH.S. A previously undescribed congenital malformation of the heart: almost total absence of the myocardium of the right ventricle.Bull. Johns Hopkins Hosp.1952913197209 12978573
     [Google Scholar]
  119. WerstuckG.H. KhanM.I. FemiaG. Glucosamine-induced endoplasmic reticulum dysfunction is associated with accelerated atherosclerosis in a hyperglycemic mouse model.Diabetes20065519310110.2337/diabetes.55.01.06.db05‑0633 16380481
     [Google Scholar]
  120. YuJ. HuJ. DaiX. SCN5A mutation in Chinese patients with arrhythmogenic right ventricular dysplasia.Herz201439227127510.1007/s00059‑013‑3998‑5 24317018
     [Google Scholar]
  121. ZhouA.X. WangX. LinC.S. C/EBP-homologous protein (CHOP) in vascular smooth muscle cells regulates their proliferation in aortic explants and atherosclerotic lesions.Circ. Res.2015116111736174310.1161/CIRCRESAHA.116.305602 25872946
     [Google Scholar]
  122. EstepJ.D. SalahH.M. KapadiaS.R. HFSA scientific statement: Update on device based therapies in heart failure.J. Card. Fail.202430111472148810.1016/j.cardfail.2024.07.007 39261158
     [Google Scholar]
  123. McMurrayJ.J. PackerM. DesaiA.S. Angiotensin–neprilysin inhibition versus enalapril in heart failure.N. Engl. J. Med.20233891334610.1056/NEJMoa2213032 37407001
     [Google Scholar]
  124. DahlströmU. JhundP.S. McMurrayJ.J. The role of nonsteroidal mineralocorticoid receptor antagonists (MRA) in heart failure treatment: A review.Lancet Cardiol20236748649510.1016/S2352‑7218(23)00101‑9
     [Google Scholar]
  125. LunarIG BlancoI Fernández-Friera l, et al. Design of the β3- adrenergic agonist treatment in chronic pulmonary hypertension secondary to heart failure trial. J Am Coll Cardiol Basic Trans Sci20205431732710.1016/j.jacbts.2020.01.009 39047242
     [Google Scholar]
  126. BoehmerJ.P. TopolE.J. FergusonT. Advances in the use of implantable cardioverter defibrillators (ICD) for heart failure management.J. Cardiovasc. Electrophysiol.202334342443610.1111/jce.15342
     [Google Scholar]
  127. EidS.M. EltawilK. Al-KahtaniM.A. Antihypertensive effects of herbal medicines: A review of recent studies.Phytother. Res.2016306913927
     [Google Scholar]
  128. Eid SM, El-Mesery SH. The role of Zingiber officinale and Allium sativum in the treatment of hypertension: Mechanisms and clinical evidence.J Ethnopharmacol2017211213221
     [Google Scholar]
/content/journals/ccr/10.2174/011573403X338702250226075044
Loading
Heart Failure Management in the Modern Era: A Comprehensive Review on Medical and Device-based Interventions
Curr. Cardiol. Rev. 21, e1573403X338702 (2025); https://doi.org/10.2174/011573403X338702250226075044
/content/journals/ccr/10.2174/011573403X338702250226075044
/content/journals/ccr/10.2174/011573403X338702250226075044
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): cardiovascular disorders; etiology; Heart failure; implantable devices; medical therapy; synergetic potential

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test